News

The company along with the National Research Council Canada have identified the potential of sCLU in inducing EMT. EMT mechanism plays a key role in tumor invasion and

The first and only subcutaneously administered anti-tumor necrosis factor (TNF)-alpha therapy is approved to induce and maintain clinical response and improve endoscopic appearance of the mucosa during induction.

The therapy is indicated for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone. Xofigo was approved three months ahead of schedule under

Nuvo Europe and Immunology Group president Henrich Guntermann said that the company has been able to secure additional patent protection in the field of airway diseases for WF10

The tablets are used for the initial treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have certain epidermal growth factor receptor (EGFR) activating mutations

Panorama was launched in March 2013 for the detection of trisomy 21, trisomy 18, trisomy 13 and select sex chromosome abnormalities, such as monosomy X. Echevarne CEO Alfonso

The Phase 1 study is the first clinical study for development of SGX203 (oral beclomethasone 17, 21-dipropionate or oral BDP) against paediatric Crohn’s disease. The Study BDP-PCD-01 is

The generic equivalent of IPR Pharmaceuticals’ Zomig tablets is indicated for the acute treatment of migraine with or without aura in adults. Mylan commenced the product shipment. The

The possibility of the agreement includes two phases such as a facility preparation and readiness phase and a clinical trial supply phase. Nordion medical isotopes general manager Tom